We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-9.36%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$214M
AUM Growth
-$23.9M
Cap. Flow
+$5.9M
Cap. Flow %
2.76%
Top 10 Hldgs %
60.02%
Holding
48
New
12
Increased
9
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$4.89M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$3.99M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.32M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
5
KURA icon
Kura Oncology
KURA
+$2.63M

Top Sells

Rank Stock Value
1
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$4.46M
2
PYXS icon
Pyxis Oncology
PYXS
+$3.49M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$3.19M
4
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$2.47M
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
2 Financials 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
26
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.47M 1.16%
+49,750
New +$2.58M
MIST icon
27
Milestone Pharmaceuticals
MIST
$147M
$2.44M 1.14%
+380,000
New +$2.37M
PMVP icon
28
CALL
PMV Pharmaceuticals
PMVP
$62.4M
$2.08M 0.97%
+100,000
New +$1.76M
IOVA icon
29
Iovance Biotherapeutics
IOVA
$2.77B
$1.98M 0.92%
118,856
-61,139
-34% -$946K
LONA
30
LeonaBio Inc
LONA
$73.4M
$1.89M 0.88%
14,003
-17,000
-55% -$1.79M
VSTM icon
31
Verastem
VSTM
$545M
$1.41M 0.66%
83,079
-72,338
-47% -$1.25M
LONA
32
CALL
LeonaBio Inc
LONA
$73.4M
$1.35M 0.63%
+10,000
New +$1.05M
MTEM
33
DELISTED
Molecular Templates, Inc.
MTEM
$1.06M 0.5%
20,475
-1,025
-5% -$45.3K
VTYX
34
DELISTED
Ventyx Biosciences
VTYX
$962K 0.45%
+70,877
New +$947K
PYXS icon
35
Pyxis Oncology
PYXS
$236M
$808K 0.38%
200,000
-477,753
-70% -$3.49M
DICE
36
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$717K 0.34%
+37,500
New +$669K
ACIU icon
37
CALL
AC Immune
ACIU
$237M
$400K 0.19%
+100,000
New +$433K
IMGN
38
DELISTED
Immunogen Inc
IMGN
$262K 0.12%
+55,000
New +$305K
SEEL
39
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$248K 0.12%
77
-574
-88% -$2.47M
ENTA icon
40
Enanta Pharmaceuticals
ENTA
$392M
$164K 0.08%
+2,300
New +$150K
NUVB icon
41
Nuvation Bio
NUVB
$2.26B
$69K 0.03%
90,832
– –
ALDX icon
42
Aldeyra Therapeutics
ALDX
$93.5M
– –
-500,000
Closed -$2M
GOSS icon
43
Gossamer Bio
GOSS
$86.5M
– –
-119,843
Closed -$1.35M
GRTX
44
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-262,500
Closed -$1.21M
ALPN
45
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-230,000
Closed -$3.19M
CYT
46
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-391,974
Closed -$4.46M
SRRA
47
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-68,500
Closed -$1.49M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Acuta Capital Partners held 48 positions worth $214M, down 10% from $238M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q1 2022 filing shows 12 new, 9 increased, 9 reduced and 7 closed positions. Its largest new stake was Avadel Pharmaceuticals: 580,000 shares worth $3.96M. The largest sale was Cyteir Therapeutics, Inc. Common Stock, an estimated $4.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q1 2022 buy was Avadel Pharmaceuticals: 580,000 shares worth $3.96M.
  • Acuta Capital Partners added most to Jounce Therapeutics, Inc. Common Stock in Q1 2022, an estimated $4.89M increase.
  • Acuta Capital Partners's biggest Q1 2022 reduction was Pyxis Oncology, cutting an estimated $3.49M.
  • Acuta Capital Partners fully exited Cyteir Therapeutics, Inc. Common Stock in Q1 2022, selling an estimated $4.46M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $214M portfolio in Q1 2022.
  • Acuta Capital Partners opened 12 new positions and closed 7 in Q1 2022.
  • Acuta Capital Partners's portfolio value fell 10% quarter-over-quarter to $214M.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.